Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on August 30, 2004. The filing addresses significant changes in the company's executive leadership structure effective on the date of the report.
Key Financial Metrics
The filing text does not provide specific financial data regarding revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on personnel changes and does not include financial statements or performance metrics for the period.
Material Changes
The primary material change reported is the restructuring of the company's senior financial and operational leadership:
- Promotion: Susan Luscinski, who served as Chief Financial Officer since August 2001, was promoted to the newly created position of Chief Operating Officer. Her responsibilities now include business planning and operational improvements.
- Appointment: Bryce Chicoyne was named Chief Financial Officer. He is responsible for financial management, accounting, treasury, SEC compliance, acquisitions, and strategic planning.
- Compensation: Mr. Chicoyne was granted an option to purchase 100,000 shares of Harvard Bioscience, Inc. common stock.
Guidance, Outlook, and Risks
The filing contains a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially from anticipated results due to known and unknown risks. The document refers investors to the "Important Factors That May Affect Future Operating Results" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2003, for detailed risk factors. No specific financial guidance or outlook was provided in this report.
Investor Verification Checklist
- Verify the effective date of the leadership transition (August 30, 2004).
- Confirm the scope of responsibilities for the new Chief Operating Officer and Chief Financial Officer.
- Review the terms of the 100,000 share option granted to the new CFO.
- Consult the referenced Form 10-K (fiscal year 2003) for detailed risk factors and historical financial performance.